造影剂对食管癌调强放疗计划的影响  

Effect of Contrast Agent on IMRT Treatment Plan for Esophageal Carcinoma

作　　者：林志安[1] 张清罗[1] 侯如蓉[1] 潘惠敏[1] 

机构地区：[1]厦门大学附属中山医院肿瘤放疗科,361004

出　　处：《实用癌症杂志》2012年第6期615-617,共3页The Practical Journal of Cancer

摘　　要：目的探讨增强造影剂对食管癌调强放疗计划的影响。方法对10例食管癌进行CT平扫与增强造影,分别设计调强放疗计划,比较2个计划靶区剂量分布和危及器官的剂量体积受量。结果增强影像计划的靶区最大剂量、最小剂量、平均剂量及中位剂量,较平扫影像计划的平均高30 cGy,适形度指数和均匀性指数的比较无差异,增强影像计划的双肺平均剂量、心脏平均剂量受量高。2种计划的双肺V20、V30和脊髓最大剂量比较无差异。结论造影剂对食管癌调强放疗剂量有影响,但影响较小,可以直接在增强影像上设计放疗计划。Objective To evaluate the effect of contrast agent on IMRT treatment plan for esophageal carcinoma.Methods Ten patients of esophageal carcinoma treated with IMRT,were planned by CT image with contrast agent or not.Isodose distribution of PTV and dose-volume histogram of organ at risk were compared.Results The maximum dose、the minimum dose、 the mean dose and the median dose of PTV have a mean increase of 30 cGy in plan with contrast agent than in plan without contrast agent.No significant difference was found in the maximum dose of spinal cord、the V20 and V30 of lung 、the conformal index and the homogeneity index between the two plans.The mean dose of heart and lung were spared more in plan without contrast agent.Conclusion On the IMRT treatment plan for esophageal carcinoma,contrast agent has little effect and can be neglected.

关 键 词：食管肿瘤 调强放射治疗 放疗计划系统 CT增强 

分 类 号：R735.2[医药卫生—肿瘤]